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In-silico gene essentiality analysis 
of polyamine biosynthesis reveals 
APRT as a potential target in cancer
Jon Pey1,2, Edurne San José-Eneriz3,4, María Carmen Ochoa3,4, Iñigo Apaolaza  1, Pedro de 
Atauri5, Angel Rubio1, Xabier Cendoya1, Estíbaliz Miranda3,4, Leire Garate3,4, Marta Cascante5, 
Arkaitz Carracedo  4,6,7,8, Xabier Agirre3,4, Felipe Prosper3,4 & Francisco J. Planes1
Constraint-based modeling for genome-scale metabolic networks has emerged in the last years as a 
promising approach to elucidate drug targets in cancer. Beyond the canonical biosynthetic routes to 
produce biomass, it is of key importance to focus on metabolic routes that sustain the proliferative 
capacity through the regulation of other biological means in order to improve in-silico gene essentiality 
analyses. Polyamines are polycations with central roles in cancer cell proliferation, through the 
regulation of transcription and translation among other things, but are typically neglected in in silico 
cancer metabolic models. In this study, we analysed essential genes for the biosynthesis of polyamines. 
Our analysis corroborates the importance of previously known regulators of the pathway, such as 
Adenosylmethionine Decarboxylase 1 (AMD1) and uncovers novel enzymes predicted to be relevant for 
polyamine homeostasis. We focused on Adenine Phosphoribosyltransferase (APRT) and demonstrated 
the detrimental consequence of APRT gene silencing on different leukaemia cell lines. Our results 
highlight the importance of revisiting the metabolic models used for in-silico gene essentiality analyses 
in order to maximize the potential for drug target identification in cancer.
Constraint-based modeling (CBM) represents one of the most popular approaches within computational systems 
biology. It focuses on building, contextualizing and analysing genome-scale metabolic networks1. CBM integrates 
different types of mathematical and biophysical constraints, enabling prediction of metabolic phenotypes. In par-
ticular, CBM allows us to conduct gene essentiality analysis (GEA), which aims at determining (i) essential genes, 
defined as those genes which individual deletion is incompatible with organism/cell growth; and (ii) synthetic 
lethal genes, which refer to two (or more) non-essential genes which simultaneous deletion becomes incompati-
ble with cellular proliferation.
CBM and GEA have been successfully applied in the field of microbiology2. Growth is here modelled as the 
flux of a physiological reaction, typically named biomass equation, which involves the metabolic requirements, in 
terms of building blocks and energy, to produce biomass. GEA is accomplished by computationally finding those 
genes whose individual (or simultaneous) deletion prevents the biomass reaction from being active. Essential 
(or synthetic lethal) genes are identified by obtaining the subset of reactions fully dependent on them and then 
confirming that the maximum biomass production becomes zero when these reactions are deleted from the met-
abolic model. Note here that enzymes catalyzing metabolic reactions are usually a gene product or, in the case of 
heterodimers or multimers, the junction of several gene products. The set of genes needed for a reaction to take 
place can be inferred based on the boolean rules typically included in genome-scale metabolic networks3.
Over the last few years, different studies have emerged to extend this same approach to the field of can-
cer research, exploiting the release of high-quality human genome-scale metabolic networks3,4 and extensive 
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availability of transcriptomic and proteomic data. The first successful application of GEA in cancer was presented 
in Folger et al.5. They revealed that haem oxygenase is synthetically lethal with the tumor suppressor fumarate 
hydratase. This result was later experimentally validated, showing its relevance to treat leiomyomatosis and renal 
cell cancer6.
In order to further continue and extend this seminal work, much effort has been done in developing algo-
rithms for contextualizing a reference human metabolic network for each particular scenario mainly based on 
gene expression data. In essence, these methods aim to select the consistent subset of reactions active for a given 
cancer sample. A non-exhaustive list of this type of methods includes: GIMME7, iMAT8, FastCore9 and others10. 
With these approaches, the construction of different cancer-specific metabolic networks is now possible.
However, less work has been directed to contextualize and enrich the biomass equation in cancer. The biomass 
equation allows us to simulate the biosynthesis of essential metabolites to produce new cells, a feature of particu-
lar relevance in cancer given the highly proliferative phenotype of malignant cells. The first biomass equation 
was released by Folger et al.5, which involves 42 essential metabolites in human tissues, including nucleotides, 
deoxynucleotides, amino acids and lipids. Despite its novelty at the time, this biomass definition is limited and 
requires further development. The process of cell growth and proliferation requires metabolic reactions that do 
not directly provide metabolites used for biomass, but rather molecules that will support the activation of signal-
ling and regulatory programs. One remarkable example is 2-hydroxyglutarate, a metabolite arising from mutated 
IDH in a number of tumors11, which has been shown to modify the epigenetic profile in cancer. Other important 
oncometabolites are acetate12, succinate or fumarate13. These observations emphasize the need to consider addi-
tional cancer-specific metabolic phenotypes, which can be systematically impaired via gene essentiality analysis. 
Two recent studies have focused on this growing need, providing an extended biomass equation14 or metabolic 
requirements associated with highly migratory cancer cells15.
In this study we focused on the requirement of polyamines (spermidine, putrescine and spermine) for tumor 
cell proliferation16,17. Polyamines are oncometabolites that exert their action, at least in part, by regulating differ-
ent cancer signalling pathways18,19 and are over-produced by cancer cells20–22. Inhibition of polyamine biosynthe-
sis has been largely investigated as a potential anti-cancer strategy, leading to a number of promising targets and 
inhibitors23,24. However, polyamines are typically neglected in the biomass equation of existing in-silico cancer 
metabolic models and, therefore, a gene essentiality analysis for polyamine biosynthesis in cancer is still lacking. 
In this study, we focused on the identification of genetic perturbations that hamper polyamine production and 
propose Adenine Phosphoribosyltransferase (APRT) as a candidate target to inhibit the production of these bio-
molecules and, in turn, curb cancer cell growth.
Results
Gene essentiality analysis for polyamine biosynthesis in cancer. We used the generic cancer model 
presented in Folger et al.5, which was built based on the expression data of the NCI-60 human cancer cell line 
panel and the standard RPMI-1640 growth medium conditions used in these cell cultures. The biomass equation 
presented in Folger et al.5 was amended by including polyamines at similar levels as found in other reconstruc-
tions25 (see Methods section). Under this new scenario, we repeated the gene essentiality analysis as conducted in 
Folger et al.5. Table 1 summarizes the set of essential and synthetic lethal genes for the biosynthesis of polyamines 
arising from our computational study. Note that the results reported here were not initially obtained in Folger et 
al.5, as their role is intrinsically linked to the biosynthesis of polyamines. Given that polyamine biosynthesis plays 
a prominent role in cancer cells over healthy tissues20–22, we hypothesized that the set of essential and synthetic 
lethal genes shown in Table 1 would be tumor-specific.
AMD1, MTAP, ODC1 and SRM are directly involved in the polyamines biosynthesis and their role in cancer 
has been previously studied17. Indeed, inhibition of ODC1 with difluoromethylornithine (DFMO) is suggested to 
reduce the risk of colorectal cancer26 and targeting AMD1 with SAM486A reduces prostate cancer growth with 
negligible systemic toxic effects22. MTAP deletion is frequently observed in cancer27, suggesting that additional 
pathways compensate the lack of this gene. In particular, in the light of the recently elucidated synthetic lethality 
of MTAP with PRMT528, MTAP-deleted cells seem to rewire their metabolism to elicit an epigenetic switch that 
explains their selective advantage. Our computational analysis is not capable of predicting the side-benefits of 
depleting MTAP due to its specific nature on metabolic modeling.
Gene(s) Enzyme(s) Type
AMD1 adenosylmethionine decarboxylase Essential
MTAP 5′-methylthioadenosine phosphorylase Essential
ODC1 ornithine decarboxylase Essential
SRM spermidine synthase Essential
MAT1A & MAT2A methionine adenosyltransferase Synthetic
MAT1A & MAT2B methionine adenosyltransferase Synthetic
APRT & PNP adenine phosphoribosyltransferase & purine-nucleoside phosphorylase Synthetic
ARG1 & OAT arginase & ornithine transaminase reversible Synthetic
Table 1. List of essential and synthetic lethal genes for the biosynthesis of polyamines obtained in our cancer 
study. This list was obtained after applying gene essentiality analysis to the in-silico cancer metabolic model 
presented in Folger et al.5, using an updated biomass equation that involves putrescine, spermidine and 
spermine in the amounts typically found in other reconstructions (see Methods section).
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MAT1A & MAT2A and MAT1A & MAT2B were revealed as synthetic lethal genes in our analysis. 
Interestingly, the metabolic model presented in Folger et al.5 does not take into account tissue-specific gene 
expression. Since MAT1A is predominantly produced in the liver29, our results would suggest that MAT2A 
and MAT2B are essential genes in other cancer tissues. MAT enzymes catabolize methionine and produce 
S-adenosylmethionine (SAM), the major methyl donor in the cell and the precursor of decarboxylated SAM for 
polyamine synthesis. The results are therefore coherent with the essential nature of enzymes that are required 
for the production of polyamine precursors. In fact, the inhibition of MAT2A has been proved to decrease cell 
growth in colon cancer30.
ARG1 and OAT are the only enzymes included in the metabolic model in Folger et al.5 capable of producing 
ornithine, key precursor of polyamines. In turn, the synthetic lethality scored in our model is consistent with the 
negative consequences of ornithine ablation on polyamine production. Indeed, experiments in yeast showed that 
their inhibition significantly decreases the level of polyamines31.
Strikingly, two genes with no apparent relationship to polyamine production were highlighted as synthetic 
lethal in our model, purine-nucleoside phosphorylase (PNP) and adenine phosphoribosyltransferase (APRT). 
On the one hand, the inhibition of PNP was previously identified as a promising therapeutic strategy in T-cell 
acute lymphoblastic leukemia (T-ALL) and cutaneous T-cell lymphoma (CTCL)32. This led to the development of 
different PNP inhibitors, such as forodesine, which has been tested in a number of clinical trials33. The cytotox-
icity derived from PNP inhibition in these tumors is mediated by the accumulation of dGTP, which leads to the 
apoptosis of lymphocytes34. Interestingly, the association of PNP inhibition with the biosynthesis of polyamines 
has not been reported and requires further consideration. On the other hand, the role of APRT in cancer is poorly 
understood and constitutes an attractive target to be explored. It catalyzes the reaction that synthesizes AMP 
from adenine. Importantly, lack of APRT activity results in the accumulation of a toxic by-product of adenine, 
2,8-dihydroxyadenine (DHA)35.
Proof-of-concept of the relevance of APRT in cancer. Figure 1 shows a metabolic scheme of the 
enzymes involved in the production of polyamines in the study by Folger et al.5. Putrescine is the precursor for the 
formation of both spermidine and spermine; 5-methylthioadenosine (MTA) is a by-product in such biosynthetic 
pathway. There is only one enzyme consuming MTA, namely MTAP, which produces a molecule of adenine. It 
can be also observed that PNP and APRT consume adenine in order to produce adenosine/deoxyadenosine and 
AMP, respectively. In the cancer metabolic network presented in Folger et al.5, these reactions are the unique 
mechanisms consuming adenine.
Based on the above, the possible synthetic lethality of PNP and APRT arises as a consequence of the need to con-
sume the generated adenine when spermidine and spermine are produced. We next proceeded to evaluate the syn-
thetic lethality underlying APRT and PNP inhibition. In line with previous studies about PNP inhibition36, we focused 
on hematological malignancies, which additionally show a major dependence on polyamines than solid tumors37. In 
Figure 1. Genes and reactions involved in the biosynthesis of polyamines. Putrescine and spermine appear in an 
empty box, while spermidine in an empty dashed box. For clarity, spermidine is represented twice. Abbreviations: 
AMP: adenosine monophosphate.
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particular, B-ALL constitutes an interesting case where the synthetic lethality of PNP and APRT (if existing) could be 
relevant, since preliminary results about PNP inhibition show a significantly lower effect than in T-ALL38.
We conducted an in vitro gene silencing experiments in the B-ALL derived cell line CEMO-1. We measured 
cell proliferation over time in the following gene knockdown scenarios: i) control; ii) PNP knockdown; iii) APRT 
knockdown and iv) PNP and APRT knockdown. Results are summarized in Fig. 2, where the inhibition of APRT 
shows a relevant impact in decreasing CEMO-1 proliferation. On the other hand, the effect of PNP knockdown 
on proliferation, as well as its simultaneous knockdown with APRT, is non-significant compared to their respec-
tive controls. These results indicate that PNP and APRT are not synthetic lethal, while APRT is essential per se. 
Further details regarding the experimental protocols are included in the Methods section.
We then re-evaluated the function of PNP and APRT in order to explain the lack of experimental validation. 
A detailed analysis of the reactions associated to PNP shows that it can accept multiple substrates: adenine, gua-
nine, hypoxanthine and uracil (Supplementary Table 1). Interestingly, while PNP accepts adenine as a substrate 
in prokaryotic cells, this is not the case in human cells39. Therefore, the degradation of adenine is incorrectly 
annotated to PNP, which explains the lack of synthetic lethality. In turn, in the absence of a compensatory PNP 
activity to metabolize adenine, our results would suggest that APRT is an essential gene in this setting. To confirm 
this, we amended the reactions annotated to PNP in the cancer metabolic model presented in Folger et al.5 and 
repeated the computational analysis carried out in the previous section, finding that APRT is now essential, in 
line with the reduction in cancer cell growth elicited by APRT silencing in Fig. 2. Table 2 shows the final set of 
essential and synthetic lethal genes resulting from our computational analysis once PNP was correctly annotated.
Essentiality of APRT in acute leukemias via gene silencing. In order to provide further insights into 
the nature of APRT as essential gene, we extended the analysis and conducted a more detailed in vitro silencing 
in several acute leukemia cell lines: CEMO-1, KG-1 (Acute myeloid leukemia (AML)), PEER, MOLT-4 (T-ALL), 
and MY (B-ALL). We used three siRNAs and each of them decreased APRT expression in all cell lines tested 
as detected by Q-RT-PCR (Fig. 3A, Supplementary Fig. 3a). Furthermore, cell proliferation was dramatically 
reduced after silencing of APRT expression in CEMO-1, KG-1, PEER cell lines (Fig. 3B), achieving reductions 
greater than 60% in all cases. Note that CEMO-1 cell line exhibits a similar result as the one found in Fig. 2. 
Regarding MOLT-4 and MY cell lines, we did not find any effect in cell proliferation, suggesting that APRT is not 
essential in all cell types (Supplementary Fig. 3b).
Our metabolic modeling assumes that cancer cells will benefit from maximal polyamine synthesis. Since 
APRT was not essential in all cell lines, we performed subsequent analyses in order to evaluate the molecular 
Figure 2. Gene silencing analysis of APRT and PNP in ALL derived CEMO-1 cell line. (A and B) mRNA 
expression of the APRT and PNP genes 48h after nucleofection with the siRNAs. Data are referred to GUS 
human gene and an experimental group nucleofected with mock siRNA. Data represent mean ± standard 
deviation of four pooled experiments with similar results. C) Proliferation of CEMO-1 cell line nucleofected 
with siRNAs targeted to the indicated genes was studied by MTS. *Indicate p-value < 0.001 in a repeated 
measures ANOVA test followed by a Bonferroni post-test between the PNP and APRT groups. Data represent 
mean ± standard deviation of four pooled experiments with similar results.
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differences between cells sensitive and resistant to the silencing of the enzyme. Transcriptional analysis of these 
cells revealed changes in the abundance of mRNAs coding for polyamine biosynthetic enzymes, including 
MAT2A, MAT2B, AMD1, APRT and SRM (FDR ≤ 5%, see Methods section, Supplementary Fig. 4). Aside from 
SRM, the rest of the genes presented a lower expression in APRT-sensitive cell lines, as observed in Fig. 4A. These 
results suggest that the abundance of polyamine biosynthetic enzymes could determine the essentiality of APRT 
in cancer and confirm the association between the effect of APRT inhibition and polyamines.
Discussion
The study of cellular metabolism in cancer research has been actively reawakened in the last years. Systems biology 
approaches, based on high-throughput “omics” data and genome-scale metabolic networks, are suitable for study-
ing cancer metabolism at an unprecedented level of detail and may provide valuable insights for different relevant 
clinical questions. Here, we use CBM and gene essentiality analysis, a promising computational tool for identifying 
therapeutic targets in cancer, in order to identify novel strategies to disrupt polyamines production in cancer.
We first emphasized the need of refining constraint-based models in order to include tumor-specific pheno-
types that can be targeted via gene essentiality analysis. Much effort has been done in developing algorithms for 
contextualizing a reference human metabolic network for a particular cancer type. However, improving biomass 
equations in cancer models has received less attention. The development of cancer-specific biomass equations may 
lead to the identification of novel specific targets for malignant cells. This is shown in our study, where APRT could 
be a cancer-specific target, given that cancer cells exhibit a higher dependence on polyamines over healthy cells20–22.
Continuing this research line will undoubtedly be an important task in the next years due to the urgent need of 
developing more effective and personalized cancer therapies. In our opinion, the development of algorithms which 
are able to integrate heterogeneous –omics datasets with high-throughput gene silencing experiments, such as those 
presented in Project Achilles40, will help us to gain further insights into the metabolic requirements that sustain 
growth in different cancer types. The use of both targeted and untargeted metabolomics approaches is particular 
important to identify novel metabolic phenotypes or key metabolites involved in different tumor stages.
Our GEA reveals MTAP as an essential gene. However, MTAP is frequently deleted in cancers concomitantly 
with CDKN2A locus27. This erroneous prediction could be explained for a compensatory benefit in losing MTAP 
expression. Indeed, it has been recently shown that MTAP deletion is synthetic lethal with inhibition of PRMT528 
suggesting that epigenetic modification could outcompete the detrimental consequences of MTAP loss in poly-
amine biosynthesis. Lack of integration of metabolic and signalling networks in our computational models is a 
limitation that requires further refinement.
In the same direction, the analysis of PNP and APRT indirectly exposes the need of improving existing 
genome-scale metabolic networks of human cells. A single annotation error led to an incorrect hypothesis (syn-
thetic lethality of PNP and APRT), which was amended based on existing literature. This inconsistency was 
experimentally validated with gene silencing analysis of PNP and APRT in the ALL derived CEMO-1 cell line. In 
contrast to the information in the metabolic model considered, there is strong evidence suggesting that PNP does 
not consume adenine in human cells39. After correcting this mis-annotation, APRT turned out to be essential 
(Table 2), playing a key role in polyamine biosynthesis. We show here that iterative refinement of human meta-
bolic networks must be driven by both computational and experimental work.
The results observed for the silencing of APRT in AML and ALL are remarkable. To our knowledge, the importance 
of APRT in cancer has not been explored. Instead, the APRT deficit has been found in a rare autosomal-recessive dis-
order that is compatible with life41 and results in renal damage42. This could open a therapeutic window for drug devel-
opment. With the proof-of-concept here presented, we believe that further investigating the role of APRT in leukemias 
and other cancer types is promising and should be further considered in the future.
In particular, understanding and predicting the differential proliferative requirement of APRT for cancer cells 
is the next logical step. Our model predicts that the lack of APRT activity would result in excessive adenine. 
This metabolic scenario could have two molecular consequences leading to growth inhibition. On the one hand, 
adenine excess could be converted to DHA via xanthine dehydrogenase (XDH) (a phenomenon observed in indi-
viduals with APRT defects42 that is not considered in the metabolic model presented Folger et al.5), which in turn 
would hamper cancer cell proliferation (Supplementary Fig. 5). On the other hand, cells could reduce the flux of 
adenine production by MTAP in order to prevent the formation of DHA, and this would result in a reduction of 
polyamine production. In either case, lack of adenine clearance would be incompatible with tumor cell function.
Gene(s) Enzyme(s) Type
AMD1 adenosylmethionine decarboxylase Essential
MTAP 5′-methylthioadenosine phosphorylase Essential
ODC1 ornithine decarboxylase Essential
SRM spermidine synthase Essential
APRT adenine phosphoribosyltransferase Essential
MAT1A & MAT2A methionine adenosyltransferase Synthetic
MAT1A & MAT2B methionine adenosyltransferase Synthetic
ARG1 & OAT arginase & ornithine transaminase reversible Synthetic
Table 2. List of essential and synthetic lethal genes for the biosynthesis of polyamines obtained in our cancer 
study once PNP annotation was corrected. With respect to Table 1, PNP and APRT are removed as synthetic 
lethal genes, while APRT now appears as essential gene.
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Resistance to APRT knockdown could be achieved in the presence of alternative enzymes for adenine con-
sumption or co-existing alterations in polyamine production genes. With respect to alternative enzymes for 
adenine consumption, different transporters could facilitate the excretion of accumulated adenine, including 
SLC29A1 and SLC29A243, as well as SLC43A344. However, we did not find statistically significant differences 
in our transcriptomic analysis between cells resistant and sensitive to APRT knockdown, thus suggesting that a 
compensatory effect in these cells is not at play. With regards to co-existing alterations in polyamine production 
genes, MTAP deletion, for example, would lead to a reduced production of adenine. In turn, this genetic alter-
ation would uncouple polyamine flux from APRT activity and would be a determinant of sensitivity to APRT 
inhibition. Although cell lines considered in our study do not present MTAP deletion, we cannot discard that 
other alternative pathways may arise for the synthesis of polyamines. For all the above, further experimental 
demonstration of the metabolic consequences of APRT inhibition is warranted.
The differential gene expression profile between cancer cells sensitive or resistant to APRT silencing pro-
vided a molecular scenario that could contribute to clarify this cell-specific essentiality. On the one hand, lower 
Figure 3. Gene silencing analysis of APRT in acute leukemias cell lines. (A) mRNA expression of APRT gene 
48h after nucleofection with the siRNAs. Data are referred to GUS human gene and an experimental group 
nucleofected with Silencer Select Negative Control-1 siRNA (Mock siRNA). (B) Cell proliferation of CEMO-1, 
KG-1 and PEER cell lines nucleofected with APRT siRNAs studied by MTS. Data represent mean ± standard 
deviation of three different experiments.
Figure 4. Gene expression analysis of cells sensitive and resistant to APRT knockdown for genes involved in the 
polyamines biosynthesis pathway. (A) Log (base 2) fold change estimates of differentially expressed genes (adj. 
p-value ≤ 0.05) involved in polyamines biosynthesis pathway. A gene with a positive fold change is upregulated 
in cells sensitive to APRT knockdown; (B) Boxplot of Log (base 2) APRT/SRM ratio in cells sensitive and 
resistant to APRT knockdown.
www.nature.com/scientificreports/
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expression of APRT in sensitive cell lines could imply that gene silencing results in a more profound depletion 
of the enzyme and hence a higher anti-proliferative effect (a threshold effect). On the other hand, the expression 
of SRM was upregulated in sensitive cell lines. This may indicate that the production of spermidine and adenine 
would be higher than in the resistant counterparts and, consequently, the pool of excessive adenine upon APRT 
inhibition would be increased. To reinforce this hypothesis, we computed the ratio of APRT/SRM (Fig. 4B). This 
ratio would reflect the production of adenine derived from polyamine synthesis that can be metabolized to AMP. 
A high ratio would imply that AMP is efficiently produced (due to high APRT or low production of adenine from 
polyamine synthesis), whereas a low ratio would imply that adenine is accumulated (due to the insufficient APRT 
activity to metabolize adenine produced from polyamines). Based on previous studies (mentioned above), ade-
nine in excess would lead to the production of toxic DHA and growth suppression. In agreement with our data, 
cells sensitive to APRT-silencing present a low APRT/SRM ratio, suggesting that they are prone to DHA produc-
tion and tumor suppression upon APRT perturbation. It is worth noting that due to the complexity of polyamine 
biosynthetic pathway, further enrichment of this pathway including cell-specific polyamine pool sizes and the rate 
of polyamine catabolism will provide a more refined view of gene essentiality45.
Our capacity to understand and go deeper into these issues will help us to rationally target polyamine pro-
duction in different cancer types. The work presented here constitutes a step forward in this direction, opening 
an innovative way to target cancer cells through APRT inhibition. The use of integrative computational models 
in combination with heterogeneous and multidimensional molecular data is essential to address this challenge.
Methods
Constraint-based Modeling and Gene Essentiality Analysis. The core of Constraint-based Modeling 
(CBM) is the mass balance equation (Equation (1)). This equation represents the change in the concentration of a 
particular metabolite in terms of the number of molecules produced and consumed per unit of time. The concen-
tration of a metabolite c (c = 1, …, C) is denoted as xc. For readers unfamiliar with metabolic modeling, for each 
reaction r (r = 1, …, R), it is assigned a continuous flux variable vr that represents its underlying activity. The total 
number of molecules produced (consumed) by each reaction is precisely its flux (vr) multiplied by the number of 
molecules produced (consumed) per unit of flux (Scr). Scr (c = 1, …, C; r = 1, …, R) are the stoichiometric coeffi-
cients, which are grouped into the matrix S. As usual in the literature46, substrates have a negative stoichiometric 
coefficient, while products have a positive stoichiometric coefficient.
∑ = = ...
=
·S v dx
dt
c C, 1, ,
(1)r
R
cr r
c
1
When we consider metabolic networks involving a large number of metabolites and reactions, the resulting set of 
differential equations cannot be solved due to lack of experimental information (concentration data and kinetic 
parameters) and its underlying complexity. Nevertheless, equation (1) can be simplified by assuming steady state, 
i.e. there is no effective variation in the concentration of considered metabolites over time. After forcing the 
steady-state assumption, equation (1) converts to equation (2), which is the main constraint used in CBM. In the 
analysis presented in the Results section, we used the stoichiometric matrix resulting from the cancer metabolic 
model presented in Folger et al.5.
∑ = = ...
=
·S v c C0, 1, ,
(2)r
R
cr r
1
In addition, it is usual to have reversible reactions (Rev), i.e. reactions that can perform in both directions. In 
these cases their flux can be positive and negative depending if it performs in the forward and backward direction, 
respectively. On the other hand, if the reaction is defined as irreversible (Irr), it can only operate in the forward 
direction, therefore its activity must be greater or equal to zero. This is reflected in equation (3). Again, in the 
analysis presented in the Results section, we classified reactions into reversible/irreversible according to the can-
cer metabolic model presented in Folger et al.5.
≥ ∀ ∈v r Irr0, (3)r
It is also common the introduction of an upper (ur) and lower (lr) bound for metabolic fluxes, as observed in 
equation (4). As noted above, for irreversible reactions, lr = 0. In case that the growth medium is known, we fixed 
to zero fluxes for intake reactions associated with non-available substrates. When no additional experimental 
information is available, ur = M and for reversible reactions lr = −M, where M is a large positive scalar. In the 
analysis presented in the Results section, we used the same growth medium and upper and lower bounds found 
in the cancer metabolic model in Folger et al.5.
≥ ≥ = ...u v l r R, 1, , (4)r r r
The system of equations (2–4) is typically underdetermined and, therefore, we need to establish a biologically 
meaningful objective (optimization) function so as to find a particular solution. CBM allows us to identify the 
solution that maximizes the growth rate, subject to equations (2–4). To that end, an artificial reaction defining the 
metabolic requirements to produce new cells, in terms of building blocks and energy, is typically introduced. This 
artificial reaction is termed the biomass reaction and its flux represents the growth rate vbio, which is maximized:
max(v ) (5)bio
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As noted in the Results section, we used the biomass reaction defined for a generic human cell found in Folger 
et al.5 and extended it with polyamines (spermidine, putrescine and spermine) in the amounts found in other 
reconstructions (see Supplementary Note 1).
Using equations (2–5), we can conduct Gene Essentiality Analysis, which aims to determine the set of essen-
tial and synthetic lethal genes. Essential genes are those whose individual deletion disables the organism/cell to 
support growth, while synthetic lethals refer to pairs of non-essential genes whose simultaneous deletion is lethal 
for growth. We describe below a systematic algorithm to determine essential genes.
Firstly, based on boolean rules that provide the relationship between genes and their encoded enzymes (pro-
teins), available in the cancer metabolic model presented in Folger et al.5, we can find the subset of reactions 
inhibited when a particular gene g (g = 1, …, G) is not active, denoted as N(g). This constraint is added into CBM 
(through equation (4)) and the maximum growth rate (vbio) is recalculated. If the maximum growth rate is below 
a certain arbitrary threshold, then such gene g is included in the list of essential genes. This arbitrary threshold 
represents the minimum biomass production to guarantee cellular proliferation. In the study presented in this 
manuscript, we considered the minimum biomass production rate to be 10−4 units, measured in grams per dry 
weight per hour (gDW/h). A sensitivity analysis for this threshold is included in Supplementary Note 1. This 
framework can be naturally extended so as to account for double gene deletion.
We used IBM Ilog Cplex in a Matlab environment to solve the underlying linear optimization problems 
defined by equations (2–5) upon different gene knockout perturbations. The computations were carried out on a 
64 bit Intel Xeon E5-1620 v2 at 2.70 GHz (4 cores) and 16 GB of RAM.
Cell culture, nucleofection and proliferation assay. Acute leukemia cell lines were maintained in cul-
ture in RPMI 1640 medium supplemented with fetal bovine serum at 37 °C in a humid atmosphere containing 
5% CO2. All cell lines were tested for mycoplasma (MycoAlert Sample Kit, Cambrex) and no positive results 
were obtained. Gene silencing were done using a Nucleofector II device (Amaxa GmbH, Köln, Germany). Cells 
were nucleofected with Silencer Select siRNA s9655 for PNP, s1505 (APRT A), UGAGCUGGAGAUUCAGAAA 
(APRT B) and AGCUGGAGAUUCAGAAAGA (APRT C) for APRT and Silencer Select Negative Control-1 
siRNA (Ambion, Austin, TX) at a final concentration of 50nM. Briefly, 1 × 106 of cells were resuspended in 100 
µL of supplemented culture medium with 50nM of APRT siRNAs or Silencer Select Negative Control-1 siRNA 
(Ambion, Austin, TX) and nucleofected with the Amaxa nucleofector apparatus using the following programs: 
G-009 (CEMO-1), C-005 (MY, MOLT-4,), C-013 (PEER) and V-001 (KG-1). Nucleofection was performed 
twice with a 24h interval. 48h after the second nucleofection, PNP and APRT mRNA expression was analyzed by 
Q-RT-PCR (GUS was employed as the reference gene). Nucleofection efficiency was determined by flow cytome-
try using the BLOCK IT Fluorescent Oligo (Invitrogen Life Technologies, Paisley, UK).
Cell proliferation was analyzed by MTS-based CellTiter 96® Aqueous Assay (Promega Corp., Madison, WI) 
that was used following the manufacturer’s instructions. Data were calculated as the percentage of total absorb-
ance of APRT nucleofected cells/absorbance of control cells.
Q-RT-PCR. Total mRNA was extracted with Trizol© Reagent 5791 (Life Technologies, Carlsbad, CA, 
USA) following the manufacturer’s instructions. RNA concentration was quantified using NanoDrop 
Specthophotometer (NanoDrop Technologies, USA). Reverse transcription was performed on 1 µg of total RNA, 
after heating at 70 °C for 5 min, with random hexamers as reaction primers. The reaction was carried out at 42 °C 
for 45 min in the presence SuperScript® II Reverse Transcriptase (Life Technologies, Carlsbad, CA, USA).
Real time PCR was performed in a 7300 Real Time System (Applied Biosystems, Foster City, CA), using 
20ng of cDNA in 12 µl reaction volume with 0.25 µmol/l of each primer (APRT F: 5′-cactctgtgggcctcctatt-3′; 
APRT R: 5′-agatcatccacgacgaccac-3′; PNP F: 5′-catgctgatccgtgaccata-3′; PNP R: 5′-atcagacatggcagggaaac3′; GUS 
F: 5′-gaaaatatgtggttggagagctcatt-3′; GUS R: 5′-ccgagtgaagatccccttttta-3′), and SYBR® Green PCR Master Mix 
(Life Technologies, Carlsbad, CA, USA). Amplification of glucuronidase beta (GUS) transcript was performed 
as a reference gene using specific primers and TaqMan probe (Applied Biosystems, Foster City, CA). The relative 
expression of each gene was quantified by the Log 2(−ΔΔCt) method using the gene GUS as an endogenous control.
Gene expression data. We carried out a differential expression analysis between cells sensitive and resistant 
to APRT knockdown. In particular, we compared 3 samples of PEER (sensitive) and 3 samples of KG-1 (sensi-
tive) against 5 samples of MOLT-4 (resistant). For the rest of cell lines considered in the main text, we could not 
find public microarrays data available. Microarrays data were obtained from Gene Expression Omnibus47. See 
Supplementary Table 2 for details of samples used in this analysis. We background corrected microarray data, 
applied quantile normalization and log2. For differential expression analysis between the two conditions, we used 
the limma package48 and selected those genes with an adjusted p-value < 0.05 using FDR approach.
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